Lee JS, Schuldt R, Xia Z, Lee L, Biondo JML, Shapiro AD
Plain Language Summary:
This study found that most people with hemophilia A who started emicizumab, a treatment used to prevent bleeding, continued taking it regularly during their first year of treatment. About three out of four patients were highly adherent to the medication, and most did not stop treatment.
These real-world findings suggest that emicizumab is a treatment that many people with hemophilia A can use consistently, which may help improve bleeding prevention and overall health outcomes.
